[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201300244A1 - Композиции и способы для лечения сердечно-сосудистого заболевания - Google Patents

Композиции и способы для лечения сердечно-сосудистого заболевания

Info

Publication number
EA201300244A1
EA201300244A1 EA201300244A EA201300244A EA201300244A1 EA 201300244 A1 EA201300244 A1 EA 201300244A1 EA 201300244 A EA201300244 A EA 201300244A EA 201300244 A EA201300244 A EA 201300244A EA 201300244 A1 EA201300244 A1 EA 201300244A1
Authority
EA
Eurasian Patent Office
Prior art keywords
electrokinetically modified
fluids
methods
administering
electrokinetically
Prior art date
Application number
EA201300244A
Other languages
English (en)
Inventor
Ричард Л. Уотсон
Энтони Б. Вуд
Грегори Дж. Аршамбо
Original Assignee
Ревалезио Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ревалезио Корпорейшн filed Critical Ревалезио Корпорейшн
Publication of EA201300244A1 publication Critical patent/EA201300244A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Описаны способы для лечения сердечно-сосудистых заболеваний и родственных состояний и симптомов (например, сердечной аритмии, сосудистого заболевания, инфаркта миокарда, застойной сердечной недостаточности, миокардита, атеросклероза и рестеноза), включающие введение нуждающемуся в этом субъекту терапевтически эффективного количества электрокинетически измененной водной жидкости, как это описано в тексте данной заявки. В отдельных аспектах электрокинетически измененные водные жидкости включают водный ионный раствор кислородсодержащих наноструктур со стабилизированным зарядом, которые преимущественно имеют средний диаметр менее чем примерно 100 нм, что достаточно для обеспечения модуляции по меньшей мере одного потенциала клеточной мембраны и проводимости клеточной мембраны. Описаны способы введения или композиции электрокинетически измененных жидкостей (например, электрокинетически измененных обогащенных газом жидкостей и растворов) и терапевтические композиции, а также использование электрокинетически измененных водных жидкостей в хирургическом контексте, включая, но не ограничиваясь, операции, относящиеся к сердечно-сосудистой системе. Кроме того, дополнительные аспекты описывают способы измерения биологической активности электрокинетически измененных жидкостей.
EA201300244A 2010-08-13 2011-08-12 Композиции и способы для лечения сердечно-сосудистого заболевания EA201300244A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37349410P 2010-08-13 2010-08-13
US201161485071P 2011-05-11 2011-05-11
PCT/US2011/047673 WO2012021860A1 (en) 2010-08-13 2011-08-12 Compositions and methods for treating cardiovascular disease

Publications (1)

Publication Number Publication Date
EA201300244A1 true EA201300244A1 (ru) 2014-01-30

Family

ID=45564974

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300244A EA201300244A1 (ru) 2010-08-13 2011-08-12 Композиции и способы для лечения сердечно-сосудистого заболевания

Country Status (11)

Country Link
US (1) US20120039884A1 (ru)
EP (1) EP2603199A4 (ru)
JP (1) JP2013538803A (ru)
KR (1) KR20130100126A (ru)
CN (1) CN103347493A (ru)
AU (1) AU2011289176B2 (ru)
BR (1) BR112013003186A2 (ru)
CA (1) CA2808192A1 (ru)
EA (1) EA201300244A1 (ru)
MX (1) MX2013001749A (ru)
WO (1) WO2012021860A1 (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7654728B2 (en) * 1997-10-24 2010-02-02 Revalesio Corporation System and method for therapeutic application of dissolved oxygen
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
US20110075507A1 (en) * 1997-10-24 2011-03-31 Revalesio Corporation Diffuser/emulsifier
US8784898B2 (en) 2006-10-25 2014-07-22 Revalesio Corporation Methods of wound care and treatment
US7832920B2 (en) * 2006-10-25 2010-11-16 Revalesio Corporation Mixing device for creating an output mixture by mixing a first material and a second material
US8784897B2 (en) * 2006-10-25 2014-07-22 Revalesio Corporation Methods of therapeutic treatment of eyes
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
US8609148B2 (en) * 2006-10-25 2013-12-17 Revalesio Corporation Methods of therapeutic treatment of eyes
US8597689B2 (en) 2006-10-25 2013-12-03 Revalesio Corporation Methods of wound care and treatment
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US20100303917A1 (en) * 2007-10-25 2010-12-02 Revalesio Corporation Compositions and methods for treating cystic fibrosis
US20100009008A1 (en) * 2007-10-25 2010-01-14 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US9745567B2 (en) * 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US20090263495A1 (en) * 2007-10-25 2009-10-22 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US20090227018A1 (en) * 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20100029764A1 (en) * 2007-10-25 2010-02-04 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20100015235A1 (en) * 2008-04-28 2010-01-21 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US20100303918A1 (en) * 2007-10-25 2010-12-02 Revalesio Corporation Compositions and methods for treating asthma and other lung disorders
EP2285347A4 (en) * 2008-05-01 2011-09-21 Revalesio Corp COMPOSITIONS AND METHODS OF TREATING DISORDERS OF THE DIGESTION SYSTEM
US20100098687A1 (en) * 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions
US20100098659A1 (en) * 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
US8815292B2 (en) * 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
CN104983740A (zh) 2010-05-07 2015-10-21 利发利希奥公司 用于增强生理性能和恢复时间的组合物和方法
AU2011289172B2 (en) 2010-08-12 2015-09-24 Revalesio Corporation Compositions and methods for treatment of taupathy
US20190298653A1 (en) * 2016-05-13 2019-10-03 Sigma-Technology Inc. Administrable aqueous solution to living body and method for manufacturing same
US10022397B2 (en) * 2016-06-20 2018-07-17 Nobilis Therapeutics, Inc. Treatment of rheumatoid arthritis using noble gas mixtures
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
CN108310010B (zh) * 2018-04-03 2021-01-12 中国科学院上海硅酸盐研究所 一种能够用于治疗心肌梗死的离子试剂及其制备方法和应用
JP2021525796A (ja) * 2018-05-25 2021-09-27 レヴァレシオ・コーポレーション 神経疾患の阻害
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
WO2020047394A1 (en) * 2018-08-31 2020-03-05 The Trustees Of The University Of Pennsylvania Injectable hydrogels for local delivery to the heart
WO2020262540A1 (ja) * 2019-06-26 2020-12-30 武田薬品工業株式会社 トランスフェクション方法
JP6760630B1 (ja) * 2019-10-29 2020-09-23 学校法人 愛知医科大学 微小気泡含有電解質液の製造方法および微小気泡含有電解質液の調製に用いる微小気泡含有溶媒の製造方法
WO2022036309A2 (en) * 2020-08-14 2022-02-17 Mayo Foundation For Medical Education And Research Methods and materials for tissue ablation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8597689B2 (en) * 2006-10-25 2013-12-03 Revalesio Corporation Methods of wound care and treatment
US7544365B2 (en) * 2006-12-14 2009-06-09 The Hospital For Sick Children TRPV1+ sensory neurons control of β-cells stress and islet inflammation in diabetes
US20090227018A1 (en) * 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
CA2703672A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20100015235A1 (en) * 2008-04-28 2010-01-21 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US9745567B2 (en) * 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US20100008997A1 (en) * 2007-10-25 2010-01-14 Revalesio Corporation Compositions and methods for treating asthma and other lung disorders
US20100098659A1 (en) * 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
JP2011001271A (ja) * 2009-06-16 2011-01-06 Tomio Ota 輸液

Also Published As

Publication number Publication date
EP2603199A4 (en) 2014-01-01
EP2603199A1 (en) 2013-06-19
AU2011289176B2 (en) 2015-09-24
CA2808192A1 (en) 2012-02-16
CN103347493A (zh) 2013-10-09
KR20130100126A (ko) 2013-09-09
WO2012021860A1 (en) 2012-02-16
JP2013538803A (ja) 2013-10-17
MX2013001749A (es) 2014-03-05
US20120039884A1 (en) 2012-02-16
AU2011289176A1 (en) 2013-03-28
BR112013003186A2 (pt) 2016-06-07

Similar Documents

Publication Publication Date Title
EA201300244A1 (ru) Композиции и способы для лечения сердечно-сосудистого заболевания
Sabbah et al. Nitroxyl (HNO) a novel approach for the acute treatment of heart failure
EA201100440A1 (ru) Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
EA201391521A1 (ru) Композиции и способы для ингибирования и/или модулирования эффекторных t-клеток, участвующих в воспалительном нейродегенеративном заболевании
SG10201803833WA (en) Heterocyclic compounds useful in the treatment of disease
EA201171197A1 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
Zong et al. Oxygen-vacancy-rich molybdenum carbide MXene nanonetworks for ultrasound-triggered and capturing-enhanced sonocatalytic bacteria eradication
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
WO2010091051A3 (en) Therapeutic use of specialized endothelial progenitor cells
Ohashi et al. Organic anion transporters, OAT1 and OAT3, are crucial biopterin transporters involved in bodily distribution of tetrahydrobiopterin and exclusion of its excess
DE602005017812D1 (de) Multipotente blutstammzellen aus der nabelschnur und zellbehandlungsmittel damit zur behandlung der ischämischen krankheit
RU2012107483A (ru) Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек
EA201100143A1 (ru) Длительное лечение клинически выраженной сердечной недостаточности
RU2009103367A (ru) Способ оценки эффективности лечения ишемической болезни сердца
Gradinger et al. Toxic myocarditis due to oral ingestion of hydrofluoric acid
DE602006019842D1 (de) Verwendung von lecithin als arzneimittel zur behandlung von psoriasis
JP2019521184A5 (ru)
Mirkabilovich et al. The effectiveness of ACE inhibitors and sartans patients with acute myocardial infarction in the elderly on a distant stage monitoring
Payne et al. The Matrikine Acetylated Proline-Glycine-Proline (acpgp) Couples Extracellular Matrix Fragmentation To Pulmonary Microvascular Remodeling And Pulmonary Hypertension
Epa et al. A62 LUNG FIBROSIS: FIBROBLAST BIOLOGY: Tissue Transglutaminase, A Two-Edged Sword: Epithelial Tg2 Expression Inhibits Myofibroblast Differentiation Via Prostaglandin (pg) E2
Dunaway et al. The hemodynamic response to nitrite is acute and dependent upon tissue perfusion
JP2016190833A (ja) 水素分子による乾癬患者における皮膚関節症状およびサイトカイン改善作用
Dendane et al. Case Report Reversible Myocarditis after Black Widow Spider Envenomation